15 april 2010 #16 www.erasmusmagazine.nl OP DE ARBEIDSMARKT Ontbijten met Wat nou 24/7 10 ‘Hypotheekrenteaftrek is pervers' Begin deze maand gaf ik een nieuwe collega een rondlei- ding op campus Woudestein. Hij komt uit Leiden, dus dan duik je als Rotterdammer toch wat in de excuusmodus als je zo langs onze grauwe gebouwen loopt. Weinig
UntitledVol 445 8 February 2007 doi:10.1038/nature05529 Senescence and tumour clearance is triggered by p53restoration in murine liver carcinomas Wen Xue1*, Lars Zender1*, Cornelius Miething1, Ross A. Dickins1,2, Eva Hernando3, Valery Krizhanovsky1,Carlos Cordon-Cardo3 & Scott W. Lowe1,2 Although cancer arises from a combination of mutations in onco- Animals with advanced tumours were treated with Dox to re- genes and tumour suppressor genes, the extent to which tumour establish p53 expression (Fig. 1b). Shortly after Dox administration, suppressor gene loss is required for maintaining established the p53 microRNA (miRNA) was shut off and p53 expression tumours is poorly understood. p53 is an important tumour sup- increased (Supplementary Fig. 1). Although tumours in untreated pressor that acts to restrict proliferation in response to DNA mice rapidly progressed, those in Dox-treated animals began to damage or deregulation of mitogenic oncogenes, by leading to involute and became nearly undetectable within 12 days (Fig. 1b).
the induction of various cell cycle checkpoints, apoptosis or cel- Similar results were observed in a subcutaneous setting, where lular senescence1,2. Consequently, p53 mutations increase cell pro- tumours could be accurately monitored using calliper measurements liferation and survival, and in some settings promote genomic (Fig. 1c, left panel). Importantly, ras-induced liver carcinomas pro- instability and resistance to certain chemotherapies3. To deter- duced using a constitutive p53 shRNA grew similarly irrespective of mine the consequences of reactivating the p53 pathway in Dox treatment (Fig. 1c, right), indicating that tumour regression was tumours, we used RNA interference (RNAi) to conditionally regu- not due to Dox toxicity. Such regressions also occurred when p53 was late endogenous p53 expression in a mosaic mouse model of liver reactivated in tumours co-expressing a constitutively activated Akt carcinoma4,5. We show that even brief reactivation of endogenous or an endogenous oncogenic K-ras allele and the conditional p53 p53 in p53-deficient tumours can produce complete tumour shRNA (W.X., L.Z. and S.W.L., unpublished data).
regressions. The primary response to p53 was not apoptosis, but To determine whether transient p53 reactivation could also cause instead involved the induction of a cellular senescence program tumour regression, we treated transformed cells in culture or that was associated with differentiation and the upregulation of tumour-bearing mice with Dox for 4 days and then removed the inflammatory cytokines. This program, although producing only drug. Immunoblotting revealed that p53 could be transiently cell cycle arrest in vitro, also triggered an innate immune response induced following Dox addition and withdrawal (Fig. 1d). In cul- that targeted the tumour cells in vivo, thereby contributing to tured cells, even two days of Dox treatment reduced colony forma- tumour clearance. Our study indicates that p53 loss can be tion to levels observed following continuous Dox treatment required for the maintenance of aggressive carcinomas, and illus- (Supplementary Fig. 2a). Furthermore, both in situ and subcutan- trates how the cellular senescence program can act together with eous liver carcinomas showed complete regressions after only four the innate immune system to potently limit tumour growth.
days of Dox treatment (Fig. 1e; Supplementary Fig. 2b). Thus, p53 p53 mutations are common in human liver cancer6, which is typ- can induce tumour involution through a process that, once activated, ically highly aggressive and resistant to non-surgical therapies. To seems irreversible. These observations are analogous to results seen determine the requirement for p53 loss in the maintenance of such in murine tumours conditionally expressing various oncogenes, carcinomas, we used reversible RNAi7 to control p53 in a chimaeric where silencing of the initiating oncogene often causes tumour liver cancer mouse model (Fig. 1a)4,5. Purified embryonic liver pro- genitor cells (hepatoblasts) were transduced with retroviruses expres- The rapid involution of hepatocarcinomas re-expressing p53 is sing oncogenic ras (HrasV12), the tetracycline transactivator protein consistent with p53's well-characterized ability to promote apopto- tTA (‘tet-off') and a tet-responsive p53 miR30 design short hairpin sis. We therefore examined apoptosis and proliferation in tumours RNA (shRNA; Supplementary Fig. 1a)7,8, and seeded into the livers of before and after p53 restoration (Fig. 2a, b). Surprisingly, we athymic nude mice following intrasplenic injection4,5. To facilitate in observed few cells that were TUNEL-positive or contained activated vivo imaging, the oncogenic ras retrovirus co-expressed green fluor- caspase 3 following p53 reactivation, suggesting that the primary escent protein (GFP) and, in some experiments, hepatoblasts were response to p53 was not apoptosis. Similarly, substantial necrosis also co-transduced with a luciferase reporter.
was not observed in the regressing tumours. Instead, these tumours p53 expression was efficiently suppressed in the absence of showed a marked decrease in proliferation (Ki67) that was associated doxycycline (Dox) and rapidly restored following Dox addition with signs of cellular differentiation (Supplementary Fig. 3).
(Supplementary Fig. 1b, c). On transplantation into the livers of p53 can also promote cellular senescence, an apparently irrevers- recipient mice, hepatoblast populations co-expressing Ras and the ible form of cell cycle arrest that is a potent barrier to tumori- conditional p53 shRNA rapidly produced invasive hepatocarcinomas genesis11–14 and can be triggered by hyperactive Ras or PI3K in the absence of Dox (Fig. 1b), whereas cells expressing each vector signalling12,15. Interestingly, hepatocarcinomas expressing either alone did not (data not shown). These tumours were GFP-positive oncogenic ras or Akt showed clear signs of senescence following p53 and, if expressing luciferase, could be visualized externally by bio- reactivation in vivo (Fig. 3a–c; data not shown for Akt), including the luminescence imaging (Fig. 1b).
accumulation of senescence-associated-b-galactosidase (SA-b-Gal) 1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA. 2Howard Hughes Medical Institute, Cold Spring Harbor, New York 11724, USA. 3Division of MolecularPathology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.
*These authors contributed equally to this work.
2007 Nature Publishing Group
NATURE Vol 445 8 February 2007 activity (Fig. 3a, b) and the senescence markers p16INK4a, DcR2 and inflammatory response, followed by destruction of tumour cells and p15INK4b (Fig. 3c)13,15. SA-b-gal activity was also observed in tumours following brief Dox treatment (Fig. 3b), indicating that a pulse of p53 Senescent cells often acquire a gene expression signature that activity was sufficient to trigger senescence in vivo.
includes the upregulation of inflammatory cytokines and other im- That p53 activation induces both cellular senescence and tumour mune modulators16,17. Accordingly, inflammatory cytokines known involution is surprising given that senescence is a cytostatic program.
to attract macrophages (Csf1 and Mcp1), neutrophils (Cxcl1) and Indeed, transformed cells accumulated SA-b-gal activity but sub- natural killer cells (Il15) were upregulated in liver tumours shortly sequently remained arrested following p53 reactivation in vitro following p53 reactivation (Fig. 4g). These genes were also induced (Fig. 3d–f), suggesting that tumour regression involves non-cell- by p53 in cultured hepatoma cells, demonstrating that they are autonomous processes. Microscopic examination of tumours har- expressed in tumour cells, not merely the infiltrating leukocytes vested at different times following p53 reactivation revealed a (Fig. 4g). Moreover, several adhesion molecules including Icam1 progressive inflammatory reaction involving polymorphonuclear (ref. 18) and Vcam1 were induced following p53 reactivation leukocytes, initially developing in peri-tumoral regions and ulti- (Fig. 4g, and data not shown), indicating one way in which senescent mately spreading throughout the tumour (Fig. 4a–f). We also cells could facilitate immune recognition. Finally, transcripts observed an intense perivascular infiltration in regressing tumours, specific for neutrophils (Ncf2, Ncf4), macrophages (Mgl2, MSR2, leading eventually to an overt vasculitis characterized by sclerosed CD68) and natural killer cells (Klrb1, Klrd1) were increased in sen- vessels, hemorraghia and erythrophagocytosis (Supplementary Fig.
escent tumours but not cultured cells. Thus, multiple components 7). Morphological, immunofluorescence and flow cytometric ana- of the innate immune system infiltrate the tumours following p53 lyses identified the infiltrating leukocytes as neutrophils, macro- phages and natural killer cells (Supplementary Figures 4–6). These To determine whether innate immune cells were required for histopathological features support a model of sequential events, tumour clearance, mice bearing subcutaneous hepatocarcinomas initiated by p53 reactivation in the tumour, activation of a dramatic harbouring the conditional p53 shRNA were treated with gadolinium Colour barMin = 1 × 105 Colour barMin = 1 × 105 Figure 1 Reactivation of p53 results in liver tumour regression.
progenitor cells with tet-off shRNA (TRE.shp53) or a non-regulatable a, Embryonic liver progenitor cells were transduced with a tetracycline- shRNA (MLS.shp53) were grown in nude mice. Values represent regulatable p53 shRNA (TRE.shp53), tTA and H-rasV12. After onset of liver mean 6 s.d. (n 5 4). d, p53 reactivation is reversed by Dox withdrawal.
tumours, p53 expression could be restored by doxycycline (Dox) treatment.
Protein lysates from liver progenitor cells pulse-treated with Dox for 4 days b, Reactivation of p53 leads to rapid tumour regression. Tumour-bearing were immunoblotted for p53. e, Representative mice (n 5 6) as in b were mice were treated with Dox starting at day 0 and imaged at the indicated time pulse-treated with Dox for 4 days and imaged at the indicated time.
points (n 5 9). c, Subcutaneous tumours derived from ras-transformed liver 2007 Nature Publishing Group
NATURE Vol 445 8 February 2007 chloride (a macrophage toxin)19,20 or neutralizing antibodies to sup- reactivation in murine sarcomas also can induce senescence and press neutrophil or natural killer cell function20,21, and monitored for tumour clearance in a completely immunocompetent setting24.
tumour regression following Dox treatment. All three treatments Our study used regulatable RNAi to demonstrate that p53 loss is significantly delayed tumour regression following p53 reactivation required for maintenance of aggressive hepatocarcinomas. We sus- (Fig. 4i), thus confirming that components of the innate immune pect that tumours harbouring p53 mutations may be hypersensitive system were actively involved in tumour clearance, presumably to restoration of p53 signalling because they have oncogenic lesions through a coordinated response. Importantly, each antagonist effi- or damage signals capable of potently activating p53 (refs 3,25). Still, ciently and specifically depleted the targeted immune cells from the the consequences of restoring p53 signalling may depend on tumour spleen or peripheral blood (Supplementary Fig. 8), but did not pre- origin or genotype; thus, whereas p53 reactivation induces sen- vent tumour cell senescence (Fig. 4j). Similarly, almost no tumour escence in liver carcinomas and sarcomas, lymphoid tumours regression was observed following p53 reactivation in tumours respond to p53 by undergoing apoptosis24. Tumours may also even- grown in NOD/SCID mice —which have a highly impaired innate tually escape their dependence on p53 mutations, but the fact that immune system22—even though p53 still induced cytostasis and sen- brief reactivation can cause complete tumour regressions supports escence (Supplementary Fig. 9). Therefore, the delay in tumour clear- the potential of transient p53 reactivation therapies26,27, even for ance cannot be explained by a failure of the immune system to advanced cancers.
phagocytose dead or dying cells. Instead, these results indicate that Our results also identify a novel mechanism of tumour suppres- the induction of cellular senescence and the evoked immune attack sion involving cooperative interactions between a tumour cell sen- cooperate to promote tumour clearance. Of note, the athymic nude escence program and the innate immune system. They further mice used here lacked functional B and T cells, which typically poten- demonstrate that, despite the cytostatic nature of the senescence tiate, but can also attenuate, inflammatory responses23. However, p53 program, senescent cells can turn over in vivo. Whether such turn-over is a general feature of senescence in vivo is not clear14,28, but whenpresent may reinforce the tumour suppressive action of senescence inpre-malignant settings or in tumours following treatment with sen- escence- or differentiation-promoting therapies26,29. Conversely, ourresults identify a setting in which the innate immune system is pro-voked to coordinately attack tumour cells, presumably through both phagocytosis and direct cytotoxic killing, thereby facilitating theirelimination. Although it is established that chronic inflammationtriggered by senescent stromal cells or other factors can promotetumorigenesis19,30, our study illustrates how innate immune cells—when targeted against senescent tumour cells—can have anti-tumoureffects as well. Strategies that specifically harness these processes may represent a promising therapeutic approach.
β-Gal positive (%) Figure 3 p53 reactivation induces cellular senescence. a, SA-b-Gal staining of representative tumour-bearing livers untreated (p53 off) ortreated with Dox (p53 on, day 6) (n 5 3). b, SA-b-Gal staining of tumour sections (n 5 3). Tumours were either untreated (p53 off), constantly Figure 2 The primary response to p53 reactivation is not apoptosis.
treated with Dox for 8 days (p53 on 8 days) or briefly treated for 4 days and a, Haematoxylin and eosin (H&E) immunohistochemical staining for left untreated for 8 days (p53 on 4 days/off 8 days). Scale bar, 25 mm.
apoptotic cells (TUNEL and Caspase 3 staining) and proliferating cells (Ki67 c, Immunoblotting for senescence markers in normal liver or liver tumours staining) of liver tumours before (p53 off) and after Dox treatment (p53 on).
treated with Dox for 0, 4 and 6 days. d, Liver progenitor cells harbouring ras Tumours showed histopathology of human hepatocellular and and tet-off shp53 were cultured in Dox-containing medium for 6 days (p53 cholangiocellular carcinoma. Inset (P) denotes positive controls (irradiated on) and stained for SA-b-Gal. Values represent mean 6 s.d. (n 5 3; thymus, 20Gy (20 Gray)). ‘p53 on' shows representative tumour on day 6.
**P , 0.0001). e, Representative pictures from d. f, Cells as in d were Scale bar, 100 mm. b, Quantification of a. Values represent mean 6 s.d.
cultured with (p53 on, red line) or without Dox (p53 off, black line) and cell (n 5 4; **P , 0.002).
numbers were counted. Values represent mean 6 s.d. (n 5 4).
2007 Nature Publishing Group
NATURE Vol 445 8 February 2007 tissue were fixed with 1% formalin for 1 min and stained for 12 h. Tumour-bearing livers were fixed with 4% formalin overnight and stained for 4 h.
Cultured cells were fixed with 4% formalin for 5 min and stained for 10 h.
RNA expression analyses. RNA isolation (Qiagen) and TaqMan reverse tran- scriptase reaction (Applied Bosystems) were according to the manufacturer's instructions. Quantitative PCR (qPCR) reactions (Bio-Rad) for each sample were done in triplicate. Microarray experiments were performed on MouseGenome 430A 2.0 arrays (Affymetrix).
Data analysis. All the statistical analysis was done by Student's t-test.
Received 26 September; accepted 13 December 2006.
Published online 24 January 2007.
Harris, S. L. & Levine, A. J. The p53 pathway: positive and negative feedback loops.
Oncogene 24, 2899–2908 (2005).
Sherr, C. J. Principles of tumor suppression. Cell 116, 235–246 (2004).
Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307–315 (2004).
Zender, L. et al. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb. Symp. Quant. Biol. 70, 251–261 (2005).
Zender, L. et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125, 1253–1267 (2006).
Below detection threshold Staib, F., Hussain, S. P., Hofseth, L. J., Wang, X. W. & Harris, C. C. TP53 and liver carcinogenesis. Hum. Mutat. 21, 201–216 (2003).
Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genet. 37, 1289–1295 (2005).
Silva, J. M. et al. Second-generation shRNA libraries covering the mouse andhuman genomes. Nature Genet. 37, 1281–1288 (2005).
Immune cell transcript Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).
10. Jain, M. et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297, 102–104 (2002).
Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660–665 (2005).
12. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Isotype control Anti-NK Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).
13. Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).
Relative tumour volume 14. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005).
Figure 4 Clearance of liver tumours by an innate immune response.
15. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras a–f, Progressive immune infiltration in regressing tumours following p53 provokes premature cell senescence associated with accumulation of p53 andp16INK4a. Cell 88, 593–602 (1997).
reactivation (H&E; n 5 4). Arrows denote peri-tumoral polymorphonuclear 16. Minamino, T. et al. Ras induces vascular smooth muscle cell senescence and (PMN) leukocytes. Arrowheads denote intra-tumoral polymorphonuclear inflammation in human atherosclerosis. Circulation 108, 2264–2269 leukocytes. Scale bar, 100 mm. e, High magnification view of d. g, p53 reactivation leads to increased expression of chemokines and adhesion 17. Shelton, D. N., Chang, E., Whittier, P. S., Choi, D. & Funk, W. D. Microarray analysis molecules in senescent tumours (in vivo) and cultured liver progenitor cells of replicative senescence. Curr. Biol. 9, 939–945 (1999).
(in vitro). Values represent mean 6 s.d. (duplicate samples with triplicate 18. Gorgoulis, V. G. et al. p53-dependent ICAM-1 overexpression in senescent qPCR). All the D4 and D8 values are statistically significant compared with human cells identified in atherosclerotic lesions. Lab. Invest. 85, 502–511 D0 (P , 0.05). h, p53 reactivation is accompanied by increased immune cell transcripts in senescent tumours (in vivo) but not in cultured cells (in vitro).
19. Maeda, S., Kamata, H., Luo, J. L., Leffert, H. & Karin, M. IKKb couples hepatocyte Values represent the average of duplicate samples from microarrays.
death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977–990 (2005).
, Subcutaneous hepatocarcinomas were treated with Dox to induce tumour 20. Mundt, B. et al. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J.
regression. The macrophage toxin GdCl (red line), an anti-neutrophil 17, 94–96 (2003).
antibody (purple) or an anti-natural killer-cell antibody (blue) was 21. Hong, F. et al. b-glucan functions as an adjuvant for monoclonal antibody administered. Saline (solid black line) or an isotype control antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res.
(dashed black line) served as controls. Values represent mean 6 s.d. (n 5 4; 63, 9023–9031 (2003).
*P , 0.02; **P , 0.002 for day 16). j, Blockade of innate immune cells does 22. Shultz, L. D. et al. Multiple defects in innate and adaptive immunologic function in not prevent p53-induced senescence. Frozen sections from control animals NOD/LtSz-scid mice. J. Immunol. 154, 180–191 (1995).
or immune antagonist treated animals were stained for SA-b-Gal activity 23. Ghiringhelli, F., Menard, C., Martin, F. & Zitvogel, L. The role of regulatory T cells in (n 5 3). Scale bar, 50 mm.
the control of natural killer cells: relevance during tumor progression. Immunol.
Rev. 214, 229–238 (2006).
24. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature advance online publication, doi:10.1038/nature05541 (24 January2007).
See Supplementary Methods for detailed experimental methods.
25. Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The Generation and analysis of liver tumours. Isolation, culture and retroviral pathological response to DNA damage does not contribute to p53-mediated infection of murine hepatoblasts were as described4,5. Doxycycline treatment tumour suppression. Nature 443, 214–217 (2006).
(BD Biosciences) and bioluminescence imaging (Xenogen) was performed 26. Bykov, V. J. et al. Restoration of the tumor suppressor function to mutant p53 according to the manufacturer's instructions. Histopathological evaluation by a low-molecular-weight compound. Nature Med. 8, 282–288 was performed by an experienced pathologist (C.C.C.). Immunohisto- 27. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule chemistry was performed as described5.
antagonists of MDM2. Science 303, 844–848 (2004).
Tumour characterization. Fresh tumour tissue was lysed in Laemmli buffer 28. Gray-Schopfer, V. C. et al. Cellular senescence in naevi and immortalisation in using a tissue homogenizer and analysed by immunoblotting by standard pro- melanoma: a role for p16? Br. J. Cancer 95, 496–505 (2006).
cedures with the indicated antibodies. Detection of SA-b-gal activity was per- 29. Roninson, I. B. Tumor cell senescence in cancer treatment. Cancer Res. 63, formed as described at pH 5.5 (ref. 7). Sections (10 mm) of snap frozen tumour 2705–2715 (2003).
2007 Nature Publishing Group
NATURE Vol 445 8 February 2007 30. Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. Y. & Campisi, J. Senescent Edith Seligson, the Don Monti Foundation, and grants from the National Institutes fibroblasts promote epithelial cell growth and tumorigenesis: a link between of Health (C.C.C, S.W.L.). This work is dedicated to our friend and colleague Dr.
cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072–12077 Enrique (Henry) Cepero.
Author Contributions W.X.: study design and conduction of experiments; L.Z.: Supplementary Information is linked to the online version of the paper at study design and conduction of experiments; C.M.: design and conduction of flow cytometry experiments; R.A.D.: vector development; E.H.: histopathologicalanalyses; V.K.: microarray analysis; C.C.C: histopathological analyses; S.W.L.: Acknowledgements We thank L. Bianco and M. Jiao for technical assistance. We study design, principal investigator.
also thank G. Evan, T. Jacks, A. Ventura, M. Narita, A. Chicas, M. Yon, G. Hannonand other members of the Lowe and Hannon laboratories for advice and Author Information Reprints and permissions information is available at discussions. We thank M. McCurrach for editorial assistance. W.X. is in the MCB www.nature.com/reprints. The authors declare no competing financial interests.
graduate program at Stony Brook University. This work was generously supported Correspondence and requests for materials should be addressed to S.W.L.
by the Emmy Noether Programme of the German Research Foundation, Alan and 2007 Nature Publishing Group
Cellular and molecular effects of steroid hormones on CNS excitability SHERYL S. SMITH, PHD, AND CATHERINE S. WOOLLEY, PHD ■ ABSTRACT has been shown to have activating effects on mood The steroid hormones 17β-estradiol (estradiol) and (euphoria, anxiety, or antidepressant effects), cogni-tion, sensory response, motor behavior, and seizure